Review details neuro-immune crosstalk, mast cell activation, and targeted therapies for chronic spontaneous cholinergic urticaria

Chronic spontaneous cholinergic urticaria (CSU-Chol) is a debilitating inflammatory skin disorder marked by intense pruritus and small wheals triggered by a rise in core body temperature. Its complex pathogenesis, involving neuro-immune crosstalk, aberrant mast cell activation, and cytokine network dysregulation, remains incompletely understood. Traditional antihistamines often provide insufficient relief, highlighting the need for deeper mechanistic insights and novel targeted therapies. Understanding the intricate interplay between neuropeptides released from sensory nerve endings and the immune system is crucial for developing effective treatments.

This systematic review synthesized current literature to elucidate the complex pathogenesis of chronic spontaneous cholinergic urticaria (CSU-Chol). Researchers provided an in-depth analysis of key immunological components, including aberrant mast cell activation, autoimmune responses, and dysregulation of the cytokine network. The review specifically focused on the pivotal role of neuro-immune crosstalk, detailing how neuropeptides released from sensory nerve endings engage in dialogue with the immune system. It further delineated the evolution of treatment strategies, from traditional antihistamines to emerging targeted therapies.

The review highlights that CSU-Chol pathogenesis is driven by a complex interplay of factors, with neuro-immune crosstalk identified as a pivotal mechanism in disease initiation and progression. Neuropeptides released from sensory nerve endings directly engage with the immune system, contributing to the inflammatory cascade. Aberrant mast cell activation is central to the condition, alongside autoimmune responses and dysregulation of the cytokine network. The consolidation of current knowledge provides a theoretical basis for precise clinical diagnosis and management.

The review emphasizes that emerging targeted therapies, focusing on pathways involving IgE, IL-4/IL-13, and mast cell signaling, represent significant advances beyond traditional antihistamines. These novel approaches aim to modulate specific immunological components, offering more precise and potentially effective management strategies for this challenging condition, while also highlighting promising future research directions.